mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Summary

This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.

Timeline

Start

2023-08-15

Primary completion

2026-05-27

Completion

2026-05-27

Outcome

Outcome not reported

Stopped (Business): “The Sponsor decided to discontinue development of mRNA-2736 for strategic business reasons.”

Drugs

Indications